Authors: Martha Powell, Future Science Group
Remember you can find us at booth #1.7d, or follow out Twitter updates @IDHubFSG
Pick of the Posters
1. Limitations of indicator disease testing for HIV infections: testing rates in one of the UK’s largest hospital trusts, Merriott D from East Kent Hospitals University extracted data for all patients with indicator diseases between January 2016 and December 2017, and matched cases to identify those who had received HIV testing. The authors concluded that testing is currently limited in cope and relies on busy scute physicians remembering and offering testing, although it did vary by indicator disease.
2. Next-generation sequencing technologies for the identification of Mycobacterium tuberculosis resistance patterns, Peker N from the University of Groningen, sequenced MDR-TB strains performing and analyzing both long- and shot-read sequencing, concluding the long-read sequencing correctly identified antimicrobial resistance gene mutations present in the resistance gene database used for this analysis. In addition, the authors state there is a need for a unified, continuously updated resistance database form clinical implementation of the NGS technologies to identify MDR/XDR-TB.
Best of social media #ECCMID19
Mark Wilcox – risk benefit analysis should be used every time an antibiotic is prescribed, and what factors should be included. Starting with – is an antibiotic really needed? #ECCMID2019 pic.twitter.com/RHc4emAlg7
— Juliet Elvy (@ElvyJuliet) April 14, 2019
— Patrick Harris (@padstamundo) April 14, 2019
There is a need to define indications for suppressive antibiotic treatment in prosthetic joint infections and determine the duration and definition of treatment failure. All current studies involve different populations and report different outcomes. #ECCMID2019 pic.twitter.com/xVFHpkyeBD
— dr muge cevik (@mugecevik) April 14, 2019